Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

iTabMed Approved to Start China Trials of CD3 Bi-specific for Solid Tumors

publication date: Jun 7, 2023

Shanghai iTabMed was approved to start China clinical trials of A-337, a CD3-activating bi-specific antibody targeting EpCAM, in patients with advanced solid tumors. The company says EpCAM is up-regulated and over-expressed in many solid tumors. A-337 was developed using iTabMed’s immunotherapy antibody (iTab™) platform. iTab™ is a T cell engager platform for human CD3-activating bi- and tri-specific antibodies targeting tumor associated antigens. A-337 has a similar structure to its lead candidate, A-319, which has started Phase I trials for patients with liquid tumors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here